Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.44 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7287642 | 0.93 | KMT2A (0.53) | KMT2AALDH1A1MAPTGSK3BHRH3 | |
| SCHEMBL3215720 | 0.84 | RAB9A (0.53) | KMT2AALDH1A1HRH3CES2CES1 | |
| SCHEMBL21747253 | 0.84 | NPC1 (0.55) | KMT2AALDH1A1GSK3BCES2CES1 | |
| SCHEMBL3390902 | 0.84 | ALDH1A1 (0.49) | KMT2AALDH1A1MAPTGSK3BCES2 | |
| SCHEMBL2207700 | 0.83 | KDM4E (0.51) | KMT2AALDH1A1MAPTCES1MEN1 | |
| SCHEMBL3303126 | 0.80 | GSK3B (0.49) | ALDH1A1GSK3BNPC1RAB9A | |
| SCHEMBL1670496 | 0.80 | MAPT (0.53) | KMT2AALDH1A1MAPTGSK3BCES2 | |
| SCHEMBL10595411 | 0.79 | ALDH1A1 (0.51) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7284408 | 0.77 | NPC1 (0.54) | KMT2AALDH1A1MAPTGSK3BCES2 | |
| SCHEMBL2768439 | 0.77 | TDP1 (0.59) | KMT2AALDH1A1GSK3BHRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970495-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-30 | — | — | US | disclosed |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-02 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| EP-3613742-B1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2022-12-07 | — | — | EP | disclosed |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2021-08-19 | — | — | US | disclosed |
| CN-113004271-A | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2021-06-01 | — | — | US | disclosed |
| CN-108484598-B | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3613742-A1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | Kind Pharmaceutical (CN) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | KMT2A 2472/4885ALDH1A1 1770/4885MAPT 143/4885 |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | KMT2A 2472/4885ALDH1A1 1770/4885MAPT 143/4885 |
| US-11970495-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | KMT2A 2472/4885ALDH1A1 1770/4885MAPT 143/4885 |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | KMT2A 2472/4885ALDH1A1 1770/4885MAPT 143/4885 |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | KMT2A 2472/4885ALDH1A1 1770/4885MAPT 143/4885 |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | KMT2A 2472/4885ALDH1A1 1770/4885MAPT 143/4885 |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | KMT2A 2472/4885ALDH1A1 1770/4885MAPT 143/4885 |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | KMT2A 2472/4885ALDH1A1 1770/4885MAPT 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.